Costs of adverse events associated with erlotinib or afatinib in first-line treatment of advanced EGFR-positive non-small cell lung cancer

OBJECTIVES: Epidermal growth factor receptor–tyrosine kinase inhibitors (EGFR-TKIs) are an established treatment for advanced non-small cell lung cancer (NSCLC) with EGFR mutation. According to published meta-analyses, no significant efficacy differences have been demonstrated between erlotinib and...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:Clinicoecon Outcomes Res
Main Authors: Isla, Dolores, De Castro, Javier, Juan, Oscar, Grau, Santiago, Orofino, Javier, Gordo, Rocío, Rubio-Terrés, Carlos, Rubio-Rodríguez, Darío
Formato: Artigo
Idioma:Inglês
Publicado em: Dove Medical Press 2016
Assuntos:
Original Research
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC5221482/
https://ncbi.nlm.nih.gov/pubmed/28115857
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.2147/CEOR.S121093
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados